Tucatinib
- Generic Name
- Tucatinib
- Brand Names
- Tukysa
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N8O2
- CAS Number
- 937263-43-9
- Unique Ingredient Identifier
- 234248D0HH
- Background
Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other ch...
- Indication
本品与曲妥珠单抗和卡培他滨联用治疗人类表皮生长因子受体2(HER2)阳性且已出现转移(如脑转移)或无法进行乳房切除术的乳腺癌成人患者，患者应接受过一种或多种抗HER2乳腺癌药物治疗。
- Associated Conditions
- Breast Cancer, Unresectable Breast Cancer, Wild-type RAS Metastatic Colorectal Cancer, Unresectable RAS Wild Type Colorectal Cancer
- Associated Therapies
- -
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 49
- Registration Number
- NCT05583110
- Locations
- 🇪🇸
Complejo hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Las Palmas, Spain
🇪🇸Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Costa del Sol, Málaga, Andalucía, Spain
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05458674
- Locations
- 🇺🇸
Cancer Care Northwest, Spokane Valley, Washington, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Swedish Cancer Institute, Issaquah, Washington, United States
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT05382364
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital-oncology of department ( Site 0010), Harbin, Heilongjiang, China
🇨🇳Hunan Cancer Hospital-Digestion and Urology ( Site 0008), Changsha, Hunan, China
🇨🇳Jilin Cancer Hospital-oncology department ( Site 0007), Changchun, Jilin, China
Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
- Conditions
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Academic and Community Cancer Research United
- Registration Number
- NCT05356897
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Carey Anders, M.D.
- Target Recruit Count
- 48
- Registration Number
- NCT05323955
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
- Conditions
- Metastatic HER2-Positive Breast CarcinomaPrognostic Stage IB Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT05319873
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05253651
- Locations
- 🇺🇸
Palo Verde Cancer Specialists, Glendale, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05230810
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- MedSIR
- Registration Number
- NCT05227131
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 654
- Registration Number
- NCT05132582
- Locations
- 🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States
🇪🇸Hospital Universitario Ramon y Cajal, Madrid, Other, Spain
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.